跳到正文
AACR 2026 现场信号· @ · X·· 2026-04-23评分60
正文 · 机器翻译

@AACR 第5天最佳试验
RMC-6236-001 | NCT06445062 | CLOVER | MYTHIC | CAR-PRISM | NCI-2018-01297 | CTEP 10355 | NCT05714072 | TROPIKANA | ZWI-ZW191-101 |
#AACR #AACR26 #AACR2026 #Cancer #Oncology #OncologyEvents #CancerResearch #OncTwitter #MedTwitter #MedX #LARVOL

热度 1 · 1 赞 · 0 回复 · 0 转发

会议摘要
LB407NCT05379985NCT06445062按 NCT NCT06445062 对上
Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal

读摘要原文 →

来源:AACR 2026 现场信号 · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org